Abstract:Background: Assessment of minimal residual disease (MRD) is actively transitioning into the mainstream routine evaluation of response to therapy and prognostication schemes in patients (pts) with acute myeloid leukemia (AML). While it is well established that pre-transplant positive MRD studies predict for relapse and transplantation outcome in pts transplanted either from matched sibling donors or matched unrelated donors, it is currently unknown whether MRD has comparable prognostic value for pts undergoing haploidentical stem cell transplantation (haplo-SCT). Methods: To analyze the prognostic impact of MRD in haplo-SCT, we performed a retrospective analysis using the ALWP multicenter registry. All adult AML pts with known MRD status at transplant who underwent a first T-cell replete related haplo-HCT in first or second complete remission from 2006 to 2016 were included. Results: Three hundred ninety-three pts of whom 265 were MRD negative and 128 were MRD positive prior to transplant met the study inclusion criteria. Median follow-up period was 26 and 15 months for MRD negative and positive pts, respectively. Compared to MRD positive pts, MRD negative pts were more likely to be NPM1wt (65% vs. 46%; P = .01) as well as harbor poor risk cytogenetics (15% vs. 7%; P < .001). Both groups of pts did not differ to a significant degree in terms of patient age, performance status, FLT3-ITDstatus, conditioning intensity, and post-transplant immunomodulation strategy (namely, use of post-transplant cyclophosphamide or anti-thymocyte globulin). In multivariate analysis, MRD negative patients experienced lower relapse incidence [Hazard ratio (HR) = .31, confidence interval (CI) 95%, .18-0.56; P < .0001] and better leukemia-free survival (LFS) (HR = .62, CI 95%, .41-0.93; P = .023) compared to MRD positive pts. Non-relapse mortality (HR = 1.34, CI 95%, .68-2.62; P = .39) and acute graft versus host disease (HR = 1.09, CI 95%, .64-1.84; P = .78) were not significantly different between both groups. Similarly, overall survival (OS) (HR = .7, CI 95%, .44-1.12; P = .14) as well as graft versus host disease-free/relapse-free survival (HR = .71, CI 95%, .48-1.04; P = .078) were not significantly impacted by MRD status. Subset analysis for MRD positive pts revealed that pts with CMV+ donors experienced decreased relapse rates (HR = .32, CI 95%, .15-0.65; P = .001) as well as increased survival (HR = .37, CI 95%, .17-0.8; P = .012). No significant predictive factors for clinical outcome were identified in the MRD negative patient subset. A landmark analysis at 6 months (figure) suggests that the clinical benefit of pre-transplant MRD negativity in terms of relapse, OS, LFS, and GRFS is realized at this time point. Conclusion: MRD negativity at transplant is associated with a reduced relapse rate and improved LFS in AML patients undergoing T-cell replete haplo-SCT.

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

Minimal Residual Disease Status in Acute Myeloid Leukemia Patients Undergoing T-Cell Replete Haploidentical Transplantation. an Analysis From the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (Ebmt)

Minimal Residual Disease Status Predicts Outcome of Acute Myeloid Leukaemia Patients Undergoing T-cell Replete Haploidentical Transplantation. an Analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications

Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma

Multiple myeloma, immunotherapy and minimal residual disease

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation

Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis

[Minimal Residual Disease Level Predicts Outcomes in the Non-Favorable Risk Patients with Acute Myeloid Leukemia].

Minimal Residual Disease-Directed Immunotherapy for High-Risk Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.

The Impact of Minimal Residual Disease Prior to Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Complete Remission

Positive Minimal Residual Disease by Multiparameter Flow Cytometry in 9 Months after Autologous Stem Cell Transplantation and High-Risk Cytogenetics Predict Poor Outcome in Multiple Myeloma

Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant.

Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia